We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Control test

15 March 2006

The German pharma group’s shares have fallen by 8% since it launched its E14bn bid for Schering. But why? The deal creates value. It may be due to Merck’s KGaA structure, which vests control in the Merck family. Outside investors have no say in what it ends up paying.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)